×
About 200 results

ALLMedicine™ Ca 15-3 Center

Research & Reviews  67 results

Prognostic Value of Combined Lactate Dehydrogenase, C-Reactive Protein, Cancer Antigen ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743925
Cancer Control : Journal of the Moffitt Cancer Center; Ma YY, Wang H et. al.

Jan 7th, 2022 - Breast cancer (BC), especially metastatic BC, is one of the most lethal diseases in women. CA 125 and CA 15-3 are commonly used indicators for diagnosis and prognosis of BC. Some serological indicators, such as lactate dehydrogenase (LDH) and C-re...

Analysis the Positive Rate of Tumor Markers Among Physical Examination Population
https://clinicaltrials.gov/ct2/show/NCT05165147

Dec 21st, 2021 - From January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study. The expression levels of carcinoembryonic antigen (CEA),α-fetoprotein (AFP), carbohydrate antigen 19-9 (CA 19-9)...

Galectin and Respiratory Weaning
https://clinicaltrials.gov/ct2/show/NCT05054556

Sep 28th, 2021 - Galectin-3 (Gal-3) is a protein with an important role in cell-cell adhesion, cell-matrix interactions, macrophage activation, angiogenesis, metastasis and apoptosis. Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, ...

A Prospective Longitudinal Breast Cancer Study
https://clinicaltrials.gov/ct2/show/NCT02270931

Aug 17th, 2021 - The study objectives are described below: Obtain serum and plasma specimens longitudinally collected from a minimum of 130 subjects diagnosed with breast cancer and are about to or are currently undergoing treatment and follow-up. Specimens will b...

Association between molecular subtype of local advanced breast cancer with Ca 15-3 level.
https://doi.org/10.3233/BD-219018
Breast Disease; Ruswendro D, Syamsu SA et. al.

Jun 8th, 2021 - Neoplasm is an abnormal mass of tissue that grows excessively and not coordinated with normal tissue growth and continues to do so even though the stimulation that triggered the change has stopped. Breast cancer can be known by using tumor marker,...

see more →

Clinicaltrials.gov  6 results

Analysis the Positive Rate of Tumor Markers Among Physical Examination Population
https://clinicaltrials.gov/ct2/show/NCT05165147

Dec 21st, 2021 - From January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study. The expression levels of carcinoembryonic antigen (CEA),α-fetoprotein (AFP), carbohydrate antigen 19-9 (CA 19-9)...

Galectin and Respiratory Weaning
https://clinicaltrials.gov/ct2/show/NCT05054556

Sep 28th, 2021 - Galectin-3 (Gal-3) is a protein with an important role in cell-cell adhesion, cell-matrix interactions, macrophage activation, angiogenesis, metastasis and apoptosis. Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, ...

A Prospective Longitudinal Breast Cancer Study
https://clinicaltrials.gov/ct2/show/NCT02270931

Aug 17th, 2021 - The study objectives are described below: Obtain serum and plasma specimens longitudinally collected from a minimum of 130 subjects diagnosed with breast cancer and are about to or are currently undergoing treatment and follow-up. Specimens will b...

Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients With Symp-tomatic Visceral Metastases or High Tumor Burden
https://clinicaltrials.gov/ct2/show/NCT04681768

Jan 11th, 2021 - Against the above discussed background there is a clear rationale to further collect real world data confirming that the use of endocrine based therapy in metastatic breast cancer is beneficial for the patient cohort with symptomatic visceral meta...

Open Label Immunotherapy Trial for Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03572361

Aug 30th, 2019 - Worldwide, breast cancer is the number one cancer in women. It affects about 12% or 1.7 mln women worldwide. In Mongolia breast cancer is less common, occupies 5-th place by frequency in women, the incidence is 118 per 100,000 or 1,770 cases per y...

see more →

News  7 results

Tumor Marker Trial Aims to Ease "Scanxiety" in Breast Cancer
https://www.onclive.com/view/tumor-marker-trial-aims-to-ease-scanxiety-in-breast-cancer

Dec 5th, 2020 - Melissa K. Accordino, MD, MS Breast surveillance is essential when determining whether or not therapy is beneficial and to avoid toxicity, usual care for patients with metastatic breast cancer includes monitoring of symptoms and cancer burden. Ho...

Net Guides: Carcinoma of Unknown Primary Orgin
https://www.onclive.com/view/net-guides-carcinoma-of-unknown-primary-orgin

Dec 5th, 2020 - //THE EDUCATED PATIENT® CUP Foundation The Cancer of Unknown Primary (CUP) Foundation is a UK-based charity organization created to provide information and support to patients with CUP. The Website has 2 informational sections: About CUP an...

Circulating Tumor DNA Testing Shows Wide-Ranging Promise in Breast Cancer
https://www.staging.medscape.com/viewarticle/894926

Apr 11th, 2018 - In the past 5 years, there has been an explosion of breast cancer research on circulating tumor DNA (ctDNA), fueled by the idea that ctDNA may provide a liquid biopsy alternative to tissue biopsies. In breast cancer, the clinical applications of c...

Lots of Unneeded Interventions in Early Breast Cancer
https://www.medscape.com/viewarticle/881573

Jun 14th, 2017 - CHICAGO – Among women who have been treated for early-stage breast cancer and are under surveillance, more than a third (37%) receive what are very likely to be unneeded tumor-marker blood tests, according to new research from the state of Washing...

A Window Into the Future of Cancer Monitoring
https://www.medscape.com/viewarticle/782736

Apr 24th, 2013 - Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer Dawson SJ, Tsui DW, Murtaza M, et al N Engl J Med. 2013;368:1199-1209 Summary In an effort to determine whether it might be possible to improve upon current methods to monitor t...

see more →